Research Article
Clinical Findings in Diabetes Mellitus Patients with COVID-19
Table 3
Treatment and outcomes of DM patients with COVID-19.
| | Total () | ICU () | Non-ICU () |
| Complications | 7 (36.8%) | 4 (57.1%) | 3 (25.0%) | Acute cardiac injury | 1 (5.3%) | 1 (14.3%) | 0 | Acute liver injury | 5 (26.3%) | 2 (28.6%) | 3 (25.0%) | Allergic eruption | 1 (5.3%) | 1 (14.3%) | 0 | Treatment | Antivirals | 18 (94.7%) | 7 (100.0%) | 11 (91.7%) | Antibiotics | 6 (31.6%) | 6 (85.7%) | 0 | Corticosteroid | 7 (36.8%) | 6 (85.7%) | 1 (8.3%) | Immunoglobulin | 6 (31.6%) | 6 (85.7%) | 0 | Insulin | 8 (42.1%) | 7 (100.0%) | 1 (8.3%) | Oxygen support | Nasal cannula | 14 (73.7%) | 4 (57.1%) | 10 (83.3%) | High-flow nasal cannula | 3 (15.85) | 3 (42.9%) | 0 | Time from symptoms onset to negative RT-PCR result, days | 22.6 (8-50) | 30.6 (19-50) | 17.9 (8-31) |
|
|
Data are presented as mean (range) or (%). Abbreviations: DM: diabetes mellitus; RT-PCR: reverse transcription-polymerase chain reaction. |